skip to main content

Phase One Clinical Trials

Moving Forward with Experimental Therapeutics

View All | Close

Molecular Targeted Trials
Phase 1 Solid Tumor Studies

2013.033 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Target: ACAT
Drug: ATR-101
Disease: Adrenocortical Carcinoma

2014.003 A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
Target: PD-L1
Drug: MEDI4736
Disease: Squamous lung and urothelial cancer

2014.005 A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Target: Nectin-4
Drug: : ASG-22CE

UMCC: 2014.057 A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Target: CD-70
Drug: SGN-CD70A

2014.071 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers
Target: PD-1/IDO
Drug: MK-3475 & INCB024360
Disease: Melanoma, urothelial, TNBC NSCLCa, DLBCL

2014.125 A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects with Solid Tumors
Target: Dll4/VEGF
Drug: OMP-305B83
Disease: Solid Tumors

2014.143 A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Subjects with Advanced Malignancies
Target: CD-40
Drug: SEA-CD40
Disease: Solid Tumors

2015.004 A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Target: PD-L1 & CTLA4
Drug: MEDI4736
Disease: Solid Tumors

2012.077 A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects Who Are Naive to Systemic Therapy
Target: PD-1
Drug: BMS-956558 (Nivolumab)
Disease:: Hepatocellular Carcinoma

2015.032 Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Target: BET/BRD
Drug: INCB054329
Disease: Solid Tumors

2015.159 A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
Target: DLL4/IgG4 kappa immunoglobulin
Drug:Demcizumab and Pembrolizumab
Disease: Solid tumors (2nd Line Non-squamous NSCLC, solid tumors- anti PD1 refractory)

2015.175 A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Target: CTLA-4
Drug: MEDI0562
Disease: Solid tumors (Dose escalation: Cervical, Bladder, SCCHN; Dose expansion: SCCHN, CC, MSS CRC< PD-L1+ NSCLC, pancreatic, prostate, UBC, IMT-relapsed/refractory)

Phase 1 Hematology Studies

updated 10.2017

back to top